Back to search

Italy· 035095013

TICLOPIDINA AUROBINDO

A ticlopidine product containing ticlopidina, registered in Italy by AUROBINDO PHARMA ITALIA S.R.L., on the national reimbursement list. The same ATC class is registered in 7 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC B01AC05

Checked against AIFA (Italy) on

Informational only — not a medical device.

SOURCE REGISTER · ITAIFA (Italy)normalisedTICLOPIDINA AUROBINDOATCB01AC05REGISTER NO.035095013PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Ticlopidine is registered in 7 of 19 countries.

Countries holding a registration under ATC B01AC05 (ticlopidine), each read from that country’s own register.

  • This record: Italy, from AIFA (Italy)
  • 5 of them publish a price we can compare per daily dose

Ticlopidine · ATC B01AC05

7 / 19 countries

  • Belgiumprice
  • Franceprice
  • Germany
  • Italyprice
  • Polandprice
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ticlopidine costs, country by country.

Normalised to the WHO defined daily dose (0.5 g), the median price runs from $0.25 in Italy to $1.0 in France — a ×4.0 gap.

  • Italy: $0.25 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Ticlopidine · price per daily dose (0.5 g)

USD · FX 28 Sept 2026

  • FR France$1.0
  • ES Spain$0.71
  • IT Italy$0.25
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

AIFA (Italy)
Active substance
Ticlopidina
Manufacturer
AUROBINDO PHARMA ITALIA S.R.L.
Country
Italy (IT)
ATC code
B01AC05
ATC class
Ticlopidine
Defined daily dose
0.5 g, O
Reimbursed
Yes
Source register
AIFA (Italy)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • aic
    035095013
    "250 MG COMPRESSE RIVESTITE" 30 COMPRESSE RIVESTITE
    EUR 3.27

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

318 interactions on record for ticlopidine.

Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ticlopidine · interactions on record

318 records

  • 54 severe
  • 124 moderate
  • 36 minor
  • 104 info

Most severe, free to view

  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • DanaparoidB01AB09severe
  • TinzaparinB01AB10severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ticlopidine in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ticlopidine products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Belgium · Ticlid, Ticlopidine Teva
  • Germany · Ticlopidin Neuraxpharm, Ticlopidine Ratiopharm
  • Spain · Ticlopidina Cinfa
  • France · Ticlopidine Arrow, Ticlopidine Eg
  • Greece · Ruxicolan Cap
  • Hungary · Aclotin, Ticlid
  • Luxembourg · Ticlid
  • Poland · Aclotin
  • Portugal · Ticlopidina, Ticlopidina Alter
  • Romania · Ticlodin
  • Slovakia · Ticlopidin Ratiopharm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AIFA (Italy). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e7d85348-a388-4024-8db1-f561ac876d6d
GET /v1/drugs/e7d85348-a388-4024-8db1-f561ac876d6d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pack": "\"250 MG COMPRESSE RIVESTITE\" 30 COMPRESSE RIVESTITE",
  "source": "aifa",
  "currency": "EUR",
  "substance": "Ticlopidina",
  "reference_pack": "30 UNITA' 250 MG - USO ORALE",
  "public_price_eur": 3.27,
  "ssn_reference_price_eur": 3.27
}

See everything about ticlopidine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.